Theseus Pharmaceuticals, Inc. (THRX) Analyst Estimates Quarterly - Discounting Cash Flows
THRX
Theseus Pharmaceuticals, Inc.
THRX (NASDAQ)
Period Ending: 2024
09-30
2024
06-30
2024
03-30
2023
12-30
2023
09-30
2023
06-30
Number of Analysts 0 0 0 0 0 0
Estimated Revenue
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EBITDA
Low None None None None None None
Average None None None None None None
High None None None None None None
Estimated EBIT
Low None None None None None None
Average None None None None None None
High None None None None None None
Estimated Net Income
Low 78.65 68.51 80.44 -18.37 -17.06 -17.35
Average 67.42 58.72 68.95 -15.75 -15.75 -14.87
High 54.31 47.3 55.54 -12.68 -14 -11.98
Estimated SGA Expenses
Low None None None None None None
Average None None None None None None
High None None None None None None
Estimated EPS
Low 1.8 1.57 1.84 -0.42 -0.39 -0.397
Average 1.54 1.34 1.58 -0.36 -0.36 -0.34
High 1.24 1.08 1.27 -0.29 -0.32 -0.274
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program